Comparison of18F-NaF PET/CT with Other Imaging Methods in the Detection of Bone Metastases in Patients with Medullary Thyroid Cancer: a Report of a Series of 31 Cases

被引:10
|
作者
Ueda, Cristina Emiko [1 ]
Duarte, Paulo Schiavom [1 ]
de Castroneves, Luciana Audi [2 ]
Coura-Filho, George Barberio [1 ]
Sado, Heitor Naoki [1 ,3 ]
Sapienza, Marcelo Tatit [3 ]
Hoff, Ana Oliveira [2 ]
Buchpiguel, Carlos Alberto [1 ,3 ]
机构
[1] Sao Paulo Canc Inst ICESP, Div Nucl Med, Sao Paulo, Brazil
[2] Sao Paulo Canc Inst ICESP, Div Endocrinol, Sao Paulo, Brazil
[3] Univ Sao Paulo FMUSP, Sch Med, Dept Radiol & Oncol, Div Nucl Med, Sao Paulo, Brazil
关键词
Fluorine; F-18; PET; CT; F-18-NaF; Medullary thyroid carcinoma; Bone metastases; F-18-FLUORIDE PET/CT; PROSTATE-CANCER; F-18-NAF PET/CT; SCINTIGRAPHY; CARCINOMA; CALCITONIN; MRI; MANAGEMENT; SPECT/CT; BREAST;
D O I
10.1007/s13139-020-00666-3
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose To compare the(18)F-NaF PET/CT studies (F-18-NaF) with other imaging methods in the detection of skeletal metastases (SM) in patients with medullary thyroid cancer (MTC). Methods We retrospectively analyzed 31 patients with MTC who performed(18)F-NaF to assess SM. The results of the(18)F-NaF were compared with other imaging methods performed for metastasis detection:Tc-99-MDP bone scan (BS), magnetic resonance imaging (MRI), contrast-enhanced CT (CT), and(68)Ga-Dotatate and(18)F-FDG PET/CT studies. A qualitative analysis comparing the(18)F-NaF findings with the ones of the other methods was performed, and the results were classified as superior (>), equal (=), and inferior (Results Eleven patients had no bone metastases detected on any of the imaging methods used. Twenty patients presented SM depicted on(18)F-NaF. Of these 20 patients, 12 performed bone scan (in 9(18)F-NaF > BS and in 3(18)F-NaF = BS), 1 performed(18)F-FDG (F-18-NaF > F-18-FDG), 4 performed(68)Ga-Dotatate (in 2(18)F-NaF > Ga-68-Dotatate and in 2(18)F-NaF = Ga-68-Dotatate), 20 performed CT of at least one body segment (in 15(18)F-NaF = CT and in 5(18)F-NaF > CT), and 16 performed MRI of at least one body segment, and in all of them, the(18)F-NaF was equal to the MRI. Beside this, the(18)F-NaF detected SM in body segments not routinely scanned in MRI and CT. Conclusion In patients with MTC, the(18)F-NaF seems to be equal or superior to other imaging modalities in the detection of SM and allows the analysis of the whole skeletal in a single study.
引用
收藏
页码:281 / 291
页数:11
相关论文
共 50 条
  • [31] Determination of the optimal imaging protocol for [18 F]PSMA-PET-CT for the detection of bone metastases in prostate cancer patients
    Bredensteiner, Linus
    Ventura, David
    Rassek, Philipp
    Schaefers, Michael
    Boegemann, Martin
    Schindler, Philipp
    Weckesser, Matthias
    Rahbar, Kambiz
    Roll, Wolfgang
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2024, 63 (05): : 287 - 293
  • [32] Superiority of 18F-FNa PET/CT for Detecting Bone Metastases in Comparison with Other Diagnostic Imaging Modalities
    Lapa, Paula
    Saraiva, Tiago
    Silva, Rodolfo
    Marques, Margarida
    Costa, Gracinda
    Lima, Joao Pedroso
    ACTA MEDICA PORTUGUESA, 2017, 30 (01): : 53 - 60
  • [33] F-18 Fluor Choline PET/CT vs F-18 Fluoride PET/CT in the detection of bone metastases in patients with prostate cancer
    Beheshti, M.
    Fitz, F.
    Haim, S.
    Nader, M.
    Poecher, S.
    Jordanova, N.
    Stoiber, F.
    Loidl, W.
    Langsteger, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S208 - S209
  • [34] Letter to the Editor: 18F-NaF not cited in the EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma
    Paulo Schiavom Duarte
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 525 - 526
  • [35] Comparison of the diagnostic performance of [18F]F-DOPA PET/CT and [18F]F-choline PET/CT in patients with recurrent medullary thyroid cancer
    Lezaic, L.
    Lezaic, E. Macek
    Rep, S.
    Zaletel, K.
    Hocevar, M.
    Jamsek, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S561 - S561
  • [36] Letter to the Editor: 18F-NaF not cited in the EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma
    Duarte, Paulo Schiavom
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (03) : 525 - 526
  • [37] F18 NaF PET/CT and whole body MRI for the detection of metastases in patients with biochemical recurrence of prostate cancer
    Twardowski, P.
    Pal, S. K.
    Stein, C.
    Frankel, P.
    Chen, H.
    Moore, T.
    Harwood, D.
    Prajapati, M.
    Junqueira, M.
    Chung, S.
    Rahmanuddin, S.
    Burns, K.
    Rodriguez, O.
    Woo, D.
    Tryon, P.
    Park, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Comparison of 18F-FDG-PET/CT with 99mTc-MDP bone scintigraphy for the detection of bone metastases in cancer patients
    Ozulker, Tamer
    Kucukoz, Aysun
    Ozulker, Filiz
    Ozpacaci, Tevfik
    NUCLEAR MEDICINE COMMUNICATIONS, 2010, 31 (06) : 597 - 603
  • [39] Comparison of Oral and IV 18F-NaF PET/CT Administration in the Assessment of Bone Metastases in Patients With Breast or Prostate Cancers
    Rocha, Nelisa Helena
    Zacchi, Samara Riguete
    Sado, Heitor Naoki
    Buchpiguel, Carlos Alberto
    Duarte, Paulo Schiavom
    Sapienza, Marcelo Tatit
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (09) : E413 - E419
  • [40] Detection of Bone Metastases in Patients with Neuroendocrine Tumors using 68Ga-DOTA-Tyr3-Octreotide PET in comparison to CT and 18F-NaF PET bone scintigraphy
    Putzer, D.
    Kendler, D.
    Henninger, B.
    Uprimny, C.
    Gabriel, M.
    Kovacs, P.
    Dobrozemsky, G.
    Decristoforo, C.
    Virgolini, I. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S132 - S132